Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Liabilities (2020 - 2023)

Historic Other Non-Current Liabilities for Kymera Therapeutics (KYMR) over the last 4 years, with Q3 2023 value amounting to $8000.0.

  • Kymera Therapeutics' Other Non-Current Liabilities fell 9687.5% to $8000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $8000.0, marking a year-over-year decrease of 9687.5%. This contributed to the annual value of $248000.0 for FY2022, which is 27575.76% up from last year.
  • According to the latest figures from Q3 2023, Kymera Therapeutics' Other Non-Current Liabilities is $8000.0, which was down 9687.5% from $230000.0 recorded in Q2 2023.
  • Over the past 5 years, Kymera Therapeutics' Other Non-Current Liabilities peaked at $273000.0 during Q1 2022, and registered a low of $8000.0 during Q3 2023.
  • Its 4-year average for Other Non-Current Liabilities is $161166.7, with a median of $165000.0 in 2020.
  • In the last 5 years, Kymera Therapeutics' Other Non-Current Liabilities soared by 27575.76% in 2022 and then plummeted by 9687.5% in 2023.
  • Quarter analysis of 4 years shows Kymera Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2020, then crashed by 34.0% to $66000.0 in 2021, then soared by 275.76% to $248000.0 in 2022, then plummeted by 96.77% to $8000.0 in 2023.
  • Its last three reported values are $8000.0 in Q3 2023, $230000.0 for Q2 2023, and $237000.0 during Q1 2023.